DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01513525

CompletedPhase 1

Comparison of Liraglutide Injected at Three Different Injection Sites in Healthy Volunteers

A Randomised, Open-label, Single Centre, Three Period Cross-over Trial in Healthy Subjects Comparing the Pharmacokinetic Profiles After Single Dose Administration of Liraglutide at Three Different Injection Sites

Lead sponsor

Novo Nordisk A/S

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

21

actual

Study population

Healthy volunteers

Key I/E criterion

•BMI 18.5-27.5

Primary endpoint

•Area under the Curve (AUC) of liraglutide for each injection site

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01513525
Org study IDNN2211-1745
Secondary ID2006-004670-27

Timeline

Milestones

Study first posted2012-01-20estimated
Last update posted2017-01-26estimated
Study start2007-02 (month precision)
Primary completion2007-05actual (month precision)
Study completion2007-05actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age18 Years
Maximum age50 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Healthy
•Good general health as judged by the Investigator based on medical history, physical examination including 12-lead ECG (electrocardiogram), vital signs and blood and urinary laboratory assessments
•BMI (Body Mass Index): 18.5-27.5 kg/m^2, both inclusive

Exclusion criteria

•Known or suspected allergy to trial product(s) or related products
•Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods as required by local law or practice
•The receipt of any investigational drug within 3 months prior to this trial
•History of any clinically significant renal, hepatic, cardiovascular, pulmonary, gastrointestinal, metabolic, endocrine, haematological, neurological, psychiatric disease or other major disorders that may interfere with the objectives of the trial, as judged by the Investigator
•Impaired renal function
•Active hepatitis B and/or active hepatitis C
•Positive human immunodeficiency virus (HIV) antibodies
•Use of any prescription or non-prescription medication, except for paracetamol and vitamins
•History of alcoholism or drug abuse during the last 12 months.
•Smoking
•Habitual excessive consumption of methylxanthine-containing (theophylline, caffeine or theobromine) beverages and foods (coffee, tea, soft drinks such as red bull, cola, chocolate) as judged by the Investigator
•Excessive consumption of a diet deviating from a normal diet as judged by the Investigator
•Blood donation within the last 3 months
•Plasma donation within the last month

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

8 endpoints
Primary/protocol endpoint

Area under the Curve (AUC) of liraglutide for each injection site

AUC₀–∞

concentration, descriptive

Secondary/protocol endpoint

AUC

AUC₀–∞

concentration, descriptive

Secondary/protocol endpoint

Cmax, maximum concentration

Cmax

concentration, descriptive

Secondary/protocol endpoint

tmax, time to maximum concentration

Tmax

descriptive

Secondary/protocol endpoint

t½, terminal half-life

Half-life

descriptive

Secondary/protocol endpoint

Terminal elimination rate constant

descriptive

Secondary/protocol endpoint

Relative Bioavailability

descriptive

Secondary/protocol endpoint

Adverse events

Treatment-emergent AEs (any)

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.